Vertex Pharmaceuticals Price Target Raised to $600

Got story updates? Submit your updates here. ›

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target increased from $540.00 to $600.00 by Oppenheimer in a research note published on Tuesday. Oppenheimer maintained an "outperform" rating on the pharmaceutical company's stock. Several other research firms have also raised their price targets on Vertex Pharmaceuticals in recent months.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing treatments for serious diseases like cystic fibrosis. The increased price target from Oppenheimer suggests Wall Street analysts see significant upside potential in the company's stock, reflecting confidence in Vertex's drug pipeline and commercial performance.

The details

Oppenheimer raised its price target on Vertex Pharmaceuticals from $540.00 to $600.00, while maintaining an "outperform" rating on the stock. Several other research firms, including Stifel Nicolaus, Barclays, Wells Fargo, and Wolfe Research, have also increased their price targets on Vertex in recent months, ranging from $466.00 to $641.00. The analysts cite Vertex's strong performance, drug pipeline, and leadership position in cystic fibrosis treatments as reasons for their optimism.

• The Oppenheimer research note was published on Tuesday, March 13, 2026.